DelveInsight’s “Cerebral Amyloid Angiopathy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Cerebral Amyloid Angiopathy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Cerebral Amyloid Angiopathy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Cerebral Amyloid Angiopathy: An Overview
Cerebral Amyloid Angiopathy (CAA), also called cerebrovascular amyloidosis, is a cerebrovascular disorder caused by the accumulation of cerebral amyloid-β (Aβ) in the tunica media and adventitia of leptomeningeal and cortical vessels of the brain. The resultant vascular fragility tends to manifest in normotensive elderly patients as lobar intracerebral hemorrhage. It is a common cerebral amyloid deposition disease, affecting ~90% of Alzheimer’s patients and increasing the risk of stroke, brain hemorrhage, or dementia.
The exact etiology of CAA is not fully understood. It is characterized by congophilic material (amyloid-beta 40 peptides) being deposited into the leptomeninges and small to medium-sized cerebral blood vessels. This deposition weakens vessel walls, making them prone to bleeding. CAA can occur in certain familial syndromes or can occur sporadically.
The most common type of CAA is caused by amyloid beta-protein (Abeta), which is particularly associated with Alzheimer’s disease (AD).
Cerebral Amyloid Angiopathy Market Key Facts
According to Steven et al. (2022), the prevalence of CAA is strongly age-dependent. The prevalence of CAA ranged from 2.3% for patients between the ages of 65 and 74, 8.0% for those aged 75 to 84, and 12.1% for patients over the age of 85.
According to Greenberg et al. (2022), the prevalence of CAA among older patients with dementia is higher than those without dementia. In a systematic review of population-based studies, nearly 60% of patients with dementia showed CAA pathology compared with less than 40 percent among those without dementia. Among patients with Alzheimer’s disease, more than 80 percent had pathologic evidence of CAA.
According to Robinson et al. (2011), the most serious manifestation of CAA in older people is the rupture of cerebral vessels, leading to primary intracerebral hemorrhage (PICH). PICH accounts for ∼10% of all strokes in the United Kingdom.
Cerebral Amyloid Angiopathy Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Cerebral Amyloid Angiopathy market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Cerebral Amyloid Angiopathy market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Cerebral Amyloid Angiopathy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Cerebral Amyloid Angiopathy Epidemiology Segmented as –
Total Prevalent Cases of Cerebral Amyloid Angiopathy (CAA) in the 7MM [2019–2032]
Age-specific Cases of Cerebral Amyloid Angiopathy (CAA) in the 7MM [2019–2032]
Severity-specific Cases of Cerebral Amyloid Angiopathy (CAA) in the 7MM [2019–2032]
Cerebral Amyloid Angiopathy Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Cerebral Amyloid Angiopathy market or expected to be launched during the study period. The analysis covers the Cerebral Amyloid Angiopathy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Cerebral Amyloid Angiopathy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Latest Key Development in the Cerebral Amyloid Angiopathy Therapeutics Landscape
On April 26, 2023, Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced positive interim results from the ongoing single ascending dose part of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy (CAA).
Learn How the Cerebral Amyloid Angiopathy Market Will Evolve and Grow by 2032 @
Cerebral Amyloid Angiopathy Therapeutics Analysis
Only a few pharma and biotech companies are developing therapies for Cerebral Amyloid Angiopathy. Currently, Alnylam Pharmaceuticals is leading the therapeutics market with its Cerebral Amyloid Angiopathy drug candidates in the most advanced stage of clinical development.
The Leading Players in the Cerebral Amyloid Angiopathy Therapeutics Market Include:
And Many Others
Cerebral Amyloid Angiopathy Therapies Covered in the Report Include:
AMDX-2011P- Amydis Inc.
Research programme: CNS disorders RNA interference–based therapeutics: Alnylam Pharmaceuticals
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Cerebral Amyloid Angiopathy Competitive Intelligence Analysis
4. Cerebral Amyloid Angiopathy Market Overview at a Glance
5. Cerebral Amyloid Angiopathy Disease Background and Overview
6. Cerebral Amyloid Angiopathy Patient Journey
7. Cerebral Amyloid Angiopathy Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Cerebral Amyloid Angiopathy Treatment Algorithm, Current Treatment, and Medical Practices
9. Cerebral Amyloid Angiopathy Unmet Needs
10. Key Endpoints of Cerebral Amyloid Angiopathy Treatment
11. Cerebral Amyloid Angiopathy Marketed Products
12. Cerebral Amyloid Angiopathy Emerging Drugs and Latest Therapeutic Advances
13. Cerebral Amyloid Angiopathy Seven Major Market Analysis
14. Attribute Analysis
15. Cerebral Amyloid Angiopathy Market Outlook (In US, EU5, and Japan)
16. Cerebral Amyloid Angiopathy Access and Reimbursement Overview
17. KOL Views on the Cerebral Amyloid Angiopathy Market
18. Cerebral Amyloid Angiopathy Market Drivers
19. Cerebral Amyloid Angiopathy Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification Services
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States